The efficacy of antiviral therapy with Peg-interferon alpha-2a plus ribavirin in patients with decompensated HCV-related cirrhosis

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONRC-12002207

Enrollment

Unknown

Registered

2012-05-28

Start date

2005-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

decompensated HCV-related cirrhosis

Interventions

therapy group:therapy with Peg-interferon alpha-2a plus ribavirin

non-therapy group:no

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria were: HCV RNA>=500 copies/mL; there are no gastrointestinal bleeding, hepatic encephalopathy, primary liver cancer and the other complications; the patient with Child-Pugh score B/C.

Exclusion criteria

Exclusion criteria: The exclusion criteria were: infection with HAV, HBV, HDV, HEVand EBV, CMV, HIV; history of alcohol and drug-induced liver disease and severe heart, brain, kidney disease.

Design outcomes

Primary

Measure	Time frame
HCV RNA;Child-Pugh score;	—

Secondary

Measure	Time frame
Disease progression;	—

Countries

China

Contacts

Public ContactWang Jiangbin

zrlwangjb@medmail.com.cn+86 0431 84995303

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026